2000
DOI: 10.1055/s-2000-14860
|View full text |Cite
|
Sign up to set email alerts
|

Patients with dyspepsia benefit from eradication of helicobacter pylori if other organic causes for dyspepsia were carefully ruled out

Abstract: HP-infection per se contributes to dyspepsia. 17 of 20 (85%) HP-positive dyspeptic patients improved after HP-eradication, when other potential organic causes for dyspepsia had been ruled out. However, many patients did not completely recover but the symptoms only partly decreased which parallels the persistence of part of the inflammatory infiltration in the gastric mucosa. This emphasizes the importance of HP-gastritis as an organic disease causing dyspeptic symptoms.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2001
2001
2003
2003

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 16 publications
(38 reference statements)
0
1
0
Order By: Relevance
“…If it is presumed that H. pylori infection has a role in the aetiology of functional dyspepsia, 4–6 we would expect a treatment related to other causes of this disorder to be less effective in H. pylori ‐positive patients if the bacterium is not eradicated simultaneously. In our trial, however, H. pylori ‐positive patients given PCC showed a substantially better treatment response, and there were no interpretable differences in treatment outcome between the two sub‐groups given placebo.…”
Section: Efficacy Variables [Values At Baseline and The End Of Treatmmentioning
confidence: 99%
“…If it is presumed that H. pylori infection has a role in the aetiology of functional dyspepsia, 4–6 we would expect a treatment related to other causes of this disorder to be less effective in H. pylori ‐positive patients if the bacterium is not eradicated simultaneously. In our trial, however, H. pylori ‐positive patients given PCC showed a substantially better treatment response, and there were no interpretable differences in treatment outcome between the two sub‐groups given placebo.…”
Section: Efficacy Variables [Values At Baseline and The End Of Treatmmentioning
confidence: 99%